Search Results: Colorectal Cancer (26 results)

This study is testing a new treatment that combines a KRAS-targeted cancer vaccine (ELI-002) with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancers with a KRAS tumor mutation and a marker known as mismatch repair proficiency (pMMR or MMR-p).

This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.

This study is testing whether a type of blood test called a liquid biopsy can find very small amounts of cancer left in the body after treatment—before cancer shows up on scans or causes symptoms.The blood test looks for circulating tumor DNA (ctDNA), tiny pieces of cancer DNA that may be present in the bloodstream. Researchers want to learn how well this test can:

• Detect cancer recurrence early
• Predict outcomes after treatment
• Support future use of blood‑based monitoring instead of—or in addition to—imaging tests

This study collects health information and DNA samples such as blood or saliva from participants to help researchers better understand cancer risk and early detection.

This clinical trial is studying whether the combination of two targeted therapies, abemaciclib (Verzenio) and a new targeted therapy  ZEN003694 (also known as ZEN-3694) can be given together safely and what dose should be used in future studies.

This phase II trial evaluates how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.

The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor. 

The purpose of this study is to find out if a medication called eRapa can help slow down the formation of polyps in people with Familial Adenomatous Polyposis (FAP).

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will depend on when they join the study. 

This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.

This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas. 

This study will examine the effectiveness and safety of cemiplimab, a treatment given prior to surgery. Participants will undergo endoscopy after the therapy and take CT scans to assess the effects of the therapy. The study also will compare genes of pretreatment cancer samples between patients who responded well to the therapy and patients who did not.

The usual care after a person with stage 3 colon cancer has had surgery and chemotherapy is to begin active surveillance. This is a time when no additional treatment is given, but instead patients have frequent imaging scans to see if their cancer has come back.

This study is looking at whether a blood test known as circulating tumor DNA (ctDNA) can find signs of remaining cancer or recurrence after treatment earlier than standard active surveillance. People in the study who have evidence of cancer in their ctDNA test may receive additional treatment based on their test results. The goal of this study is to learn if using ctDNA and additional treatment improves outcomes in people after treatment for stage 3 colon cancer. Currently, testing with ctDNA is not part of standard of care to determine if colon cancer treatment was successful or if there is a recurrence. 

This study is being done to decide if the drug Tukysa (Tucatinib) combined with other cancer drugs works better than the standard of care, which is chemotherapy treatment for people with a specific type of colorectal cancer called HER2 positive colorectal cancer. The study also aims to understand the side effects of the combination of these drugs in treatment. The combination of drugs being used are Tukysa (Tucatinib), Herceptin (Trastuzumab), and mFOLFOX6, which is a combination of Oxaliplatin, Leucovorin, Levoleucovorin, and Fluorouracil.

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. People will have blood drawn and complete a questionnaire to join the study. Genetic testing will be done on your blood and the tissue from your tumor biopsy or surgery to test the genes that you inherited. You do not have to pay for the genetic testing. You will receive the results of your test from your oncologist and genetic counseling may be recommended. Two weeks and one year after talking with your doctor about your test results, you will complete follow-up questionnaires either in person or over the phone. 

This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome and those diagnosed with early onset colorectal cancer, diagnosed younger than 50 years old. 

The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation. The study involves people with Li-Fraumeni syndrome and people from families with Li-Fraumeni syndrome filling out questionnaires with their medical information.

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.

Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.

This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss. 

Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:

• have a tumor marker known as microsatellite stable (MSS), OR
• have been treated with and no longer respond to treatment with immunotherapy drugs known as immune checkpoint inhibitors.

This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.

We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.

Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.